VEGF and angiopoietin signaling in tumor angiogenesis and metastasis

Trends in Molecular Medicine

Volumn 17, Issue 7, 2011, Pages 347-362

  Saharinen, Pipsa ^a   Eklund, Lauri ^b   Pulkki, Kristina ^a,c,d   Bono, Petri ^c   Alitalo, Kari ^a,c,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AMG 386; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN PEPTIBODY; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CEP 11981; DOVITINIB; HYBRID PROTEIN; ICRUCUMAB; MEDI 3617; MF 431C1; MF431C1; MONOCLONAL ANTIBODY; PAZOPANIB; PF 4856884; RAMUCIRUMAB; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; COLORECTAL CANCER; DRUG BINDING; DRUG INHIBITION; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC VESSELS; MODELS, ANIMAL; NEOPLASM METASTASIS; RECEPTORS, TIE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960227968     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.01.015     Document Type: Review

References (189)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
3. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 2006, 1:119-150.
4. Murdoch C., et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
5. Sica A., et al. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008, 267:204-215.
6. Folkman J., Kalluri R. Cancer without disease. Nature 2004, 427:787.
7. Holash J., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
8. Adams R.H., Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 2007, 8:464-478.
9. Makanya A.N., et al. Intussusceptive angiogenesis and its role in vascular morphogenesis, patterning, and remodeling. Angiogenesis 2009, 12:113-123.
10. Ferrara N. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 2009, 29:789-791.
11. Kim K.J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
12. Hurwitz H., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
13. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
14. Augustin H.G., et al. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 2009, 10:165-177.
15. Lee S., et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130:691-703.
16. Chappell J.C., et al. Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev. Cell 2009, 17:377-386.
17. Jakobsson L., et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat. Cell Biol. 2010, 12:943-953.
18. Phng L.K., Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev. Cell 2009, 16:196-208.
19. Benedito R., et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009, 137:1124-1135.
20. Lee S., et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 2005, 169:681-691.
21. Fukumura D., Jain R.K. Imaging angiogenesis and the microenvironment. APMIS 2008, 116:695-715.
22. Heldin C.H., et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
23. Seaman S., et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007, 11:539-554.
24. Crawford Y., Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009, 335:261-269.
25. Korsisaari N., et al. Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10625-10630.
26. Korsisaari N., et al. Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin. Cancer Res. 2008, 14:249-258.
27. Prewett M., et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999, 59:5209-5218.
28. Spratlin J.L., et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 2010, 28:780-787.
29. Holash J., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11393-11398.
30. Kim E.S., et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11399-11404.
31. Baffert F., et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H547-559.
32. Gerber H.P., et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:3478-3483.
33. Adnane L., et al. Sorafenib (BAY 43-9006 Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006, 407:597-612.
34. Llovet J.M., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
35. Motzer R.J., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27:3584-3590.
36. Sternberg C.N., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 2010, 28:1061-1068.
37. Ivy S.P., et al. An overview of small-molecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol. 2009, 6:569-579.
38. Bagri A., et al. Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends Mol. Med. 2010, 16:122-132.
39. Casanovas O., et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
40. Allegra C.J., et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J. Clin. Oncol. 2009, 27:3385-3390.
41. Van Cutsem E., et al. Lessons from the adjuvant bevacizumab trial on colon cancer: what next?. J. Clin. Oncol. 2011, 29:1-4.
42. Schmidinger M., Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat. Rev. 2010, 36:416-424.
43. Inai T., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 2004, 165:35-52.
44. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
45. Tong R.T., et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64:3731-3736.
46. Batchelor T.T., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
47. Sorensen A.G., et al. A " vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009, 69:5296-5300.
48. Winkler F., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
49. Grunewald M., et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006, 124:175-189.
50. Kane R.C., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 2006, 12:7271-7278.
51. Kindler H.L., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 2010, 28:3617-3622.
52. Xu L., et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 2009, 69:7905-7910.
53. Paez-Ribes M., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
54. Ebos J.M., et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
55. Sullivan R., Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007, 26:319-331.
56. Murdoch C., et al. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234.
57. Du R., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
58. Shojaei F., et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
59. Shojaei F., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-831.
60. Shojaei F., et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6742-6747.
61. Fischer C., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
62. Bais C., et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010, 141:166-177.
63. Wu Y., et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin. Cancer Res. 2006, 12:6573-6584.
64. Pan Q., et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007, 11:53-67.
65. Karkkainen M.J., et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 2004, 5:74-80.
66. Zhang L., et al. VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis. Cell Res. 2010, 20:1319-1331.
67. Haiko P., et al. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol. Cell. Biol. 2008, 28:4843-4850.
68. Tammela T., et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454:656-660.
69. Valtola R., et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol. 1999, 154:1381-1390.
70. Laakkonen P., et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 2007, 67:593-599.
71. Nilsson I., et al. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J. 2010, 29:1377-1388.
72. Tvorogov D., et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010, 18:630-640.
73. Eccles S.A., Welch D.R. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007, 369:1742-1757.
74. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
75. Mazzone M., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
76. Wyckoff J.B., et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007, 67:2649-2656.
77. Qian B., et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 2009, 4:e6562.
78. Kaplan R.N., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
79. Hiratsuka S., et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 2008, 10:1349-1355.
80. Dvorak H.F., et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 1999, 237:97-132.
81. Lee S.L., et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:19485-19490.
82. Stoletov K., et al. Visualizing extravasation dynamics of metastatic tumor cells. J. Cell Sci. 2010, 123:2332-2341.
83. di Tomaso E., et al. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res. 2005, 65:5740-5749.
84. Rofstad E.K., et al. Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res. 2002, 62:661-664.
85. He Y., et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005, 65:4739-4746.
86. Pathak A.P., et al. Lymph node metastasis in breast cancer xenografts is associated with increased regions of extravascular drain, lymphatic vessel area, and invasive phenotype. Cancer Res. 2006, 66:5151-5158.
87. Dadiani M., et al. Real-time imaging of lymphogenic metastasis in orthotopic human breast cancer. Cancer Res. 2006, 66:8037-8041.
88. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 2010, 21:21-26.
89. Mancuso M.R., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 2006, 116:2610-2621.
90. Ebos J.M., et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:17069-17074.
91. Gupta P.B., et al. Cancer stem cells: mirage or reality?. Nat. Med. 2009, 15:1010-1012.
92. Achen M.G., Stacker S.A. Molecular control of lymphatic metastasis. Ann. N. Y. Acad. Sci. 2008, 1131:225-234.
93. Tammela T., Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010, 140:460-476.
94. Kyzas P.A., et al. Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J. Pathol. 2005, 206:170-177.
95. Giampieri S., et al. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell Biol. 2009, 11:1287-1296.
96. Padera T.P., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
97. Wong S.Y., et al. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res. 2005, 65:9789-9798.
98. Tammela T., et al. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. Circ. Res. 2007, 100:1468-1475.
99. Hoshida T., et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res. 2006, 66:8065-8075.
100. Ruddell A., et al. Dynamic contrast-enhanced magnetic resonance imaging of tumor-induced lymph flow. Neoplasia 2008, 10:706-713. 701 p following 713.
101. Shields J.D., et al. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 2007, 11:526-538.
102. Issa A., et al. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res. 2009, 69:349-357.
103. Shields J.D., et al. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328:749-752.
104. Lin J., et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 2005, 65:6901-6909.
105. Roberts N., et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 2006, 66:2650-2657.
106. Burton J.B., et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008, 68:7828-7837.
107. Shibata M.A., et al. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene. Ther. 2008, 15:776-786.
108. Koch M., et al. VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis. J. Pathol. 2009, 219:356-364.
109. Karpanen T., et al. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 2006, 20:1462-1472.
110. Xu Y., et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J. Cell Biol. 2010, 188:115-130.
111. Caunt M., et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008, 13:331-342.
112. Murakami M., et al. VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler. Thromb. Vasc. Biol. 2008, 28:658-664.
113. Van den Eynden G.G., et al. Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. Br. J. Cancer 2006, 95:1362-1366.
114. Harrell M.I., et al. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am. J. Pathol. 2007, 170:774-786.
115. Hirakawa S., et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 2005, 201:1089-1099.
116. Hirakawa S., et al. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007, 109:1010-1017.
117. Partanen J., et al. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol. Cell. Biol. 1992, 12:1698-1707.
118. Maisonpierre P.C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
119. Daly C., et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:15491-15496.
120. Dellinger M., et al. Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. Dev. Biol. 2008, 319:309-320.
121. D'Amico G., et al. Loss of endothelial Tie1 receptor impairs lymphatic vessel development-brief report. Arterioscler. Thromb. Vasc. Biol. 2010, 30:207-209.
122. Qu X., et al. Abnormal embryonic lymphatic vessel development in Tie1 hypomorphic mice. Development 2010, 137:1285-1295.
123. Baffert F., et al. Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H107-118.
124. Li X., et al. Basal and angiopoietin-1-mediated endothelial permeability is regulated by sphingosine kinase-1. Blood 2008, 111:3489-3497.
125. Salmon A.H., et al. Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx. Cardiovasc. Res. 2009, 83:24-33.
126. Hammes H.P., et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004, 53:1104-1110.
127. Tabruyn S.P., et al. Angiopoietin-2-driven vascular remodeling in airway inflammation. Am. J. Pathol. 2010, 177:3233-3243.
128. Dumont D.J., et al. The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene 1993, 8:1293-1301.
129. Shimoda H. Immunohistochemical demonstration of Angiopoietin-2 in lymphatic vascular development. Histochem. Cell Biol. 2009, 131:231-238.
130. Fiedler U., et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004, 103:4150-4156.
131. Jang C., et al. Angiopoietin-2 exocytosis is stimulated by sphingosine-1-phosphate in human blood and lymphatic endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2009, 29:401-407.
132. Szarvas T., et al. Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin. Cancer Res. 2008, 14:8253-8262.
133. Helfrich I., et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin. Cancer Res. 2009, 15:1384-1392.
134. Fukuhara S., et al. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat. Cell Biol. 2008, 10:513-526.
135. Saharinen P., et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat. Cell Biol. 2008, 10:527-537.
136. Zhang J., et al. Angiopoietin-1/Tie2 signal augments basal Notch signal controlling vascular quiescence by inducing delta-like 4 expression through AKT-mediated activation of {beta}-catenin. J. Biol. Chem. 2011, 10.1074/jbc.M110.192641.
137. Fiedler U., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat. Med. 2006, 12:235-239.
138. Winderlich M., et al. VE-PTP controls blood vessel development by balancing Tie-2 activity. J. Cell Biol. 2009, 185:657-671.
139. Li Z., et al. Embryonic stem cell tumor model reveals role of vascular endothelial receptor tyrosine phosphatase in regulating Tie2 pathway in tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:22399-22404.
140. Lin P., et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:8829-8834.
141. Oliner J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
142. Brown J.L., et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol. Cancer Ther. 2010, 9:145-156.
143. Sarraf-Yazdi S., et al. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J. Surg. Res. 2008, 146:16-23.
144. Huang H., et al. Specifically targeting angiopoietin-2 inhibit angiogenesis, tie2 expressing monocyte infiltration and tumor growth. Clin. Cancer Res. 2011, 10.1158/1078-0432.CCR-10-2317.
145. Herbst R.S., et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J. Clin. Oncol. 2009, 27:3557-3565.
146. Mita A.C., et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin. Cancer Res. 2010, 16:3044-3056.
147. Karlan B.Y., et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J. Clin. Oncol. 2010, 28:15s. (suppl. abstr. 5000).
148. Nasarre P., et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 2009, 69:1324-1333.
149. Cao Y., et al. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res. 2007, 67:3835-3844.
150. Reiss Y., et al. Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2. J. Pathol. 2009, 217:571-580.
151. Falcon B.L., et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am. J. Pathol. 2009, 175:2159-2170.
152. Coxon A., et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol. Cancer Ther. 2010, 9:2641-2651.
153. Hwang J.A., et al. COMP-Ang1 potentiates the antitumor activity of 5-fluorouracil by improving tissue perfusion in murine Lewis lung carcinoma. Mol. Cancer Res. 2009, 7:1920-1927.
154. Hashizume H., et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010, 70:2213-2223.
155. Chae S.S., et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin. Cancer Res. 2010, 16:3618-3627.
156. Huang J., et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int. J. Oncol. 2009, 34:79-87.
157. Koh Y.J., et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 2010, 18:171-184.
158. Holopainen T., et al. Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment. Cancer Res. 2009, 69:4656-4664.
159. Tammela T., et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005, 105:4642-4648.
160. De Palma M., et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008, 14:299-311.
161. Nagy J.A., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 2002, 196:1497-1506.
162. Wirzenius M., et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J. Exp. Med. 2007, 204:1431-1440.
163. Bry M., et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 2010, 122:1725-1733.
164. Leppanen V.M., et al. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2425-2430.
165. Barton W.A., et al. Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex. Nat. Struct. Mol. Biol. 2006, 13:524-532.
166. McDonald D.M. New antibody to stop tumor angiogenesis and lymphatic spread by blocking receptor partnering. Cancer Cell 2010, 18:541-543.
167. Kendrew, J. et al. (2011) An antibody targetted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2 dependent angiogenesis without affecting ligand binding. Mol. Cancer Ther. Mar 9. [Epub ahead of print].
168. Saharinen, Alitalo Double target for tumor mass destruction. J. Clin. Invest. 2003, 111:1277-1280.
169. Saharinen, Bry, Alitalo How do angiopoietins Tie in with vascular endothelial growth factors?. Curr. Opin. Hematol. 2010, 17:198-205.
170. Rius J., et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 453:807-811.
171. Kujawski M., et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008, 118:3367-3377.
172. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
173. De Palma M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
174. Lin E.Y., et al. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol. Oncol. 2007, 1:288-302.
175. Kubota Y., et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J. Exp. Med. 2009, 206:1089-1102.
176. Coffelt S.B., et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res. 2010, 70:5270-5280.
177. Murdoch C., et al. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J. Immunol. 2007, 178:7405-7411.
178. Venneri M.A., et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007, 109:5276-5285.
179. Ojalvo L.S., et al. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am. J. Pathol. 2009, 174:1048-1064.
180. Pucci F., et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood " resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009, 114:901-914.
181. Escudier B., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
182. Tol J., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:563-572.
183. Krishnamurthi S.S., et al. Phase 1 study of weekly anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody IMC-18F1 in patients with advanced solid malignancies. J. Clin. Oncol. 2008, 26. abstract 14630, 12008 ASCO Annual Meeting.
184. Yu Y., et al. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS ONE 2010, 5:e9072.
185. Herbst R.S., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010, 11:619-626.
186. Shi M., et al. Effect of TKI258 in plasma biomarkers and pharmacokinetics in patients with advanced melanoma. J. Clin. Oncol. 2009, 27. (suppl. abstr. 9020).
187. Twardowski P., et al. Phase II study of aflibercept (VEGF-trap) in patients with recurrent or metastatic urothelial cancer, a california cancer consortium trial. Urology 2010, 76:923-926.
188. Wang F.Q., et al. VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol. Oncol. 2009, 115:414-423.
189. Rosen L.S., et al. First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. J. Clin. Oncol. 2010, 28. (suppl. abstr. 2524).